Matthew McAviney is a Partner at NEA focusing on biopharma investments, leveraging his unique background as a physician with an M. D. from the University of Illinois and an MBA from the University of Chicago. His career path includes roles in healthcare consulting at Oliver Wyman, biotechnology equity research at Robert W. Baird, and venture capital at F-Prime.
He has a robust background in science, having conducted lipid metabolism research at the National Institute of Diabetes, Digestive and Kidney Disorders and earning a BA with Honors in Biological Sciences from the University of Chicago.
His dual expertise as a trained physician and a seasoned biopharma investor gives him a distinct perspective on evaluating new therapeutic opportunities.
Matthew McAviney, M.D.
Partner at New Enterprise Associates (NEA)
San Francisco, California, United States
Overview
Topics They Care About
Biopharma Investing
As a Partner at NEA, he is responsible for biopharma investments and holds board positions at companies like AviadoBio and Recludix Pharma.
Oncology Treatments
He recently joined the board of CHARM Therapeutics, a company developing next-generation menin inhibitors to treat acute myeloid leukemia (AML).
AI in Drug Discovery
His involvement with CHARM Therapeutics, which uses an AI-driven platform to design cancer drugs, signals an interest in advanced discovery technologies.
Media Appearances
Matthew has no verified media appearances
Work History
6-2018
Partner at New Enterprise Associates (NEA)
9-2013 - 6-2018
Principal at F-Prime Capital
8-2012 - 9-2013
Associate, Health & Life Sciences Practice at Oliver Wyman
1-2011 - 8-2012
Senior Equity Research Associate, Biotechnology at Robert W. Baird & Co.
Education
2009 - 2011
MBA from The University of Chicago Booth School of Business
2007 - 2011
MD from University of Illinois College of Medicine
More Information
Social Presence :
Prographics :
Exp : 15
Location : San Francisco, California, United States
Job Level : N/A
Designation : Partner at New Enterprise Associates (NEA)
